Breaking the mold: revolutionary new obesity drugs set to transform treatment landscape?
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Article Breaking the mold: revolutionary new obesity drugs set to transform treatment landscape? was published on August 16, 2023 in the journal Journal of Basic and Clinical Physiology and Pharmacology (volume 0, issue 0).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As a nonpeptide small molecule, orforglipron does not elicit an immune response, thereby eliminating the risk of antibody formation and representing a theoretical and practical safety advantage over peptide therapies [81,82,83].”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [81]
Citations
Cites
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302392 · Cited by 478
Deng, Y., Park, A., Zhu, L., Xie, W., & Pan, C. Q. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221108064 · Cited by 51
Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective
Sidik, S. (2023) · Nature · doi:10.1038/d41586-023-02092-9 · Cited by 18
Cited by
Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031409 · Cited by 22
“As a nonpeptide small molecule, orforglipron does not elicit an immune response, thereby eliminating the risk of antibody formation and representing a theoretical and practical safety advantage over peptide therapies [81–83].”
Metadata
- Authors
- Seetharaman, R., & Pandit, S.
- Affiliations
- King Edward Memorial Hospital and Seth G.S. Medical College (IN)
- Government of Maharashtra (IN)
- Corresponding author
- Pandit, Swarnima
- Venue
- Journal of Basic and Clinical Physiology and Pharmacology
- Publisher
- Walter de Gruyter GmbH
- Published
- 2023-08-16
- Volume
- 34
- Issue
- 6
- Pages
- 689-690
- ISSN
- 0792-6855 (ISSN-L)
- 2191-0286
- OpenAlex
- W4385827169
- Cited by
- 1
- References
- 4
- Citations by year
- 2026: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Basic and Clinical Physiology and Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- obesity drugs, obesity treatment, obesity pharmacotherapy, weight loss
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Breaking the mold: revolutionary new obesity drugs set to transform treatment landscape? https://app.cochat.ai/papers/10.1515/jbcpp-2023-0172
- The paper
- Seetharaman, R., & Pandit, S. (2023). Breaking the mold: revolutionary new obesity drugs set to transform treatment landscape? Journal of Basic and Clinical Physiology and Pharmacology. https://doi.org/10.1515/jbcpp-2023-0172
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.